Inspire Medical Systems, Inc. Earnings Per Share Disclosure
| Year ended December 31, | ||||||||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| Numerator: | ||||||||||||||||||||
| Net income (loss) | $ | 145,422 | $ | 53,509 | $ | (21,153) | ||||||||||||||
| Denominator: | ||||||||||||||||||||
Weighted average number of common shares outstanding — basic | 29,368,892 | 29,763,395 | 29,302,154 | |||||||||||||||||
| Dilutive effect of stock options | 317,986 | 594,726 | — | |||||||||||||||||
| Dilutive effect of restricted stock units | 56,059 | 79,514 | — | |||||||||||||||||
| Dilutive effect of performance stock units | 11,480 | 99,263 | — | |||||||||||||||||
| Dilutive effect of shares issuable under the ESPP | 2,619 | 6,376 | — | |||||||||||||||||
Weighted average number of common shares outstanding — diluted | 29,757,036 | 30,543,274 | 29,302,154 | |||||||||||||||||
| Net income (loss) per share: | ||||||||||||||||||||
| Basic | $ | 4.95 | $ | 1.80 | $ | (0.72) | ||||||||||||||
| Diluted | $ | 4.89 | $ | 1.75 | $ | (0.72) | ||||||||||||||
| Year Ended December 31, | ||||||||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| Stock options | 1,415,769 | 1,514,718 | 2,447,141 | |||||||||||||||||
| Restricted stock units | 525,088 | 29,320 | 201,070 | |||||||||||||||||
| Total | 1,940,857 | 1,544,038 | 2,648,211 | |||||||||||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.